Sign in
TerminatedPhase 2

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Key facts

Who runs it
Memorial Sloan Kettering Cancer Center
Where
New York, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
9 people enrolled
Started
25 Jul 2018
Ended
6 Mar 2024
Type of study
Interventional, 3 groups
Treatments tested
  • Hyperfractionated total body irradiation
  • Thiotepa
  • Cyclophosphamide
  • Busulfan
  • Fludarabine
  • Melphalan
  • Clofarabine
  • HPC(A) stem cell allograft
  • Rituximab
  • Rabbit antithymocyte globulin
Record updated
6 April 2025
Why it stopped
Low accrual

Who can take part

Age
Up to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Other criteria

  • Subject Inclusion Criteria:
  • Patients with any of the following hematologic malignancies who are considered to be eligible for allogeneic transplantation:; Acute lymphoid leukemia (ALL) in first complete remission (CR1) with high risk for relapse including:; Detectable minimal residual disease by either multicolor flow cytometry or by genomic assay after initial induction therapy; t(9;22) or detected BCR-ABL1 translocation by genomic methodologies; BCR-ABL1-Like B-ALL [23] including mutations of IKZF1 or CRLF2; Translocations or mutations involving 11q23 (MLL) gene; Hypodiploid karyotype; Deletion of 9p; Loss of 17p or TP53 mutation; T-lymphocyte lineage antigen expression (T-ALL); Prior CNS or other extramedullary involvement; WBC count ≥ 100,000 cells/μL at diagnosis; Acute biphenotypic or bilineal leukemia in CR1; Acute myeloid leukemia (AML) in CR1 with; Detectable minimal residual disease (MRD) by either multicolor flow cytometry or by genomic assay after initial induction therapy; In the absence of MRD any intermediate or high risk features according to the European LeukemiaNet 2017 guidelines indlucing:
  • Mutated FL T3-ITD or FL T3-TKD
  • Cytogenetic abnormalities not classified as favorable
  • Cytogenetic abnormalities associated with myelodysplastic syndrome including abnormalities of chromosome 5, 7, or 17p
  • Complex karyotype or monosomal karyotype
  • t(9;11)(p21.1;q23.3); MLL-KMT2A or other rearrangements of KMT2A
  • t(9;11); BCR-ABL1
  • Inversions or translocations of chromosome 3
  • T(6;9)(p23;q34.1); DEK-NUP214
  • Somatic mutation of RUNX1, ASX1 or TP53; Extramedullary involvement; WBC count ≥100,000 cells/μL at diagnosis; Relapsed acute leukemia with ≤ 5% blasts in the bone marrow prior to transplantation (i.e. CR2 or greater); Myelodysplastic syndrome, myeloproliferative neoplasms, or MDS/MPN overlap syndrome with ≤ 10% blasts and at least one of the following:; Revised International Prognostic Scoring System risk score of INT, HIGH, or VERY HIGH at the time of transplant evaluation; Life-threatening cytopenias; Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype; Therapy related disease or disease evolving from other malignant processes; Chronic myelomonocytic leukemia (CMML) with ≤ 10% blasts prior to transplantation; Chronic myeloid leukemia (CML) meeting one of the following criteria:; Failed or are intolerant to BCR-ABL tyrosine kinase inhibitors; CML with BCR-ABL mutation consistent with poor response to tyrosine kinase inhibition (e.g. T351I mutation); CML with accelerated or blast phase with <10% blasts after therapy; Chronic lymphocytic leukemia (CLL) with high risk disease as defined by the EBMT consensus criteria; Hodgkin lymphoma meeting both of the following criteria:; Responding to therapy prior to enrollment; Relapse after autologous bone marrow transplant or are ineligible for autologous bone marrow transplant; °Non-Hodgkin lymphoma meeting both of the following criteria:; Responding to therapy prior to enrollment; Relapse after prior autologous bone marrow transplant or are ineligible for autologous bone marrow transplant; Patients aged from birth through 65 years old are eligible; Patients must have Karnofsky/Lanksy performance status ≥70%; Cardiac left ventricular ejection fraction ≥50% at rest; Serum bilirubin ≤ 2 mg/dL. Patients with Gilbert's disease or ongoing hemolytic anemia are acceptable if the direct bilirubin is ≤ 2 mg/dL; AST and ALT ≤ 2.5 x ULN unless thought to be disease related; Estimated or measured creatinine clearance > 50 mL/min/1.73 m\^2 body surface area; Adult patients and pediatric patients capable of performing pulmonary function studies must have hemoglobin adjusted pulmonary DLCO ≥50% of predicted; Subject Exclusion Criteria:
  • Persons with a HLA matched sibling donor or a 8/8 allele level HLA-matched unrelated donor
  • Female patients who are pregnant or breast-feeding
  • Persons with an infection that is not responding to antimicrobial therapy
  • Persons who are seropositive for HIV
  • Persons with active/detectable central nervous system malignancy
  • Persons who do not meet the age and organ function criteria specified above
  • Presence of psychiatric or neurologic disease, or lack of social support that limits the patient's ability to comply with the treatment protocol including supportive care, followup, and research tests
  • Prior allogeneic hematopoietic cell transplantation are ineligible
  • Patients with history of other malignancy within 5 years of study therapy are ineligible with the following exceptions: Low grade prostate cancer (Gleason's ≤6) treated with curative intent, breast ductal carcinoma in situ treated with curative intent, or nonmelanomatous skin carcinomas; Donor Inclusion and Exclusion Criteria:
  • Partially HLA-matched unrelated volunteers (allele level matched at 6-7 of 8 HLA loci: -A, -B, -C, and -DRB1) are eligible
  • Related, haploidentical donors are eligible
  • Able to provide informed consent to the donation process
  • Meet standard criteria for donor collection as defined by the National Marrow Donor Program Guidelines

Where in United States

  • Memorial Sloan-Kettering Cancer CenterNew York, United States

About the trial

What the trial wants to find out

This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.

The 3 groups in the trial

  • Radiation, Thiotepa & CyclophosphamideTreatment being tested

    Treatment: Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide, HPC(A) stem cell allograft, Rituximab, and Rabbit antithymocyte globulin

  • Busulfan, Fludarabine & MelphalanTreatment being tested

    Treatment: Busulfan, Fludarabine, Melphalan, HPC(A) stem cell allograft, Rituximab, and Rabbit antithymocyte globulin

  • Clofarabine, Thiotepa & MelphalanTreatment being tested

    Treatment: Thiotepa, Melphalan, Clofarabine, HPC(A) stem cell allograft, Rituximab, and Rabbit antithymocyte globulin

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Allogeneic Hematopoietic Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Record updated
6 April 2025